{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:04:51Z","timestamp":1788930291833,"version":"build-2803163510"},"reference-count":154,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","award":["01144"],"award-info":[{"award-number":["01144"]}],"id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R21 R21AA029206"],"award-info":[{"award-number":["R21 R21AA029206"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2018-12365391"],"award-info":[{"award-number":["RF-2018-12365391"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jhep.2023.08.029","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:36:40Z","timestamp":1695325000000},"page":"140-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Bioactive signalling lipids as drivers of chronic liver diseases"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-4460","authenticated-orcid":false,"given":"Eleanna","family":"Kaffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Tisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Magkrioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9531-7729","authenticated-orcid":false,"given":"Vassilis","family":"Aidinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-3671","authenticated-orcid":false,"given":"Wajahat Z.","family":"Mehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-2963","authenticated-orcid":false,"given":"Mauro","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.08.029_bib1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1439-0396.2007.00752.x","article-title":"Liver lipid metabolism","volume":"92","author":"Nguyen","year":"2008","journal-title":"J\u00a0Anim Physiol Anim Nutr (Berl)"},{"key":"10.1016\/j.jhep.2023.08.029_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03190711","article-title":"Biosynthesis of bile acids in mammalian liver","volume":"31","author":"Kevresan","year":"2006","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jhep.2023.08.029_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1051\/rnd:19960404","article-title":"Regulation of VLDL synthesis and secretion in the liver","volume":"36","author":"Gruffat","year":"1996","journal-title":"Reprod Nutr Dev"},{"key":"10.1016\/j.jhep.2023.08.029_bib4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A\u00a0position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3","volume":"33","author":"Rubbia-Brandt","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A\u00a0lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100104","article-title":"Nonalcoholic fatty liver disease stratification by liver lipidomics","volume":"62","author":"Vvedenskaya","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104949","article-title":"Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease","volume":"25","author":"Sen","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.jhep.2023.08.029_bib12","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Oresic","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.08.029_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1042\/BST20150235","article-title":"Blood triacylglycerols: a lipidomic window on diet and disease","volume":"44","author":"Sanders","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.jhep.2023.08.029_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.08.029_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-nutr-071812-161139","article-title":"Fatty acid-regulated transcription factors in the liver","volume":"33","author":"Jump","year":"2013","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.jhep.2023.08.029_bib17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2013.01.006","article-title":"Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor","volume":"58","author":"Ducheix","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib18","first-page":"1529","article-title":"Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression","volume":"38","author":"Sekiya","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clnesp.2021.06.015","article-title":"Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"44","author":"Sangouni","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.jhep.2023.08.029_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2020.06.028","article-title":"Bioactive lipids, inflammation and chronic diseases","volume":"159","author":"Leuti","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhep.2023.08.029_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101068","article-title":"Emerging roles of lysophospholipids in health and disease","volume":"80","author":"Tan","year":"2020","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbalip.2019.02.005","article-title":"Novel functions of phospholipase A(2)s: overview","volume":"1864","author":"Murakami","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jhep.2023.08.029_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27082487","article-title":"Current knowledge on mammalian phospholipase A(1), brief history, structures, biochemical and pathophysiological roles","volume":"27","author":"Yaginuma","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2023.08.029_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100378","article-title":"Ex\u00a0vivo instability of lipids in whole blood: preanalytical recommendations for clinical lipidomics studies","volume":"64","author":"Wang","year":"2023","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib25","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1194\/jlr.S087163","article-title":"MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines","volume":"59","author":"Burla","year":"2018","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.08.029_bib27","article-title":"LPIAT1\/MBOAT7 contains a catalytic dyad transferring polyunsaturated fatty acids to lysophosphatidylinositol","volume":"1866","author":"Caddeo","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jhep.2023.08.029_bib28","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49882","article-title":"Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease","volume":"8","author":"Helsley","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jhep.2023.08.029_bib29","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1194\/jlr.R046920","article-title":"Novel lysophosphoplipid receptors: their structure and function","volume":"55","author":"Makide","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.31290","article-title":"The L-alpha lysophosphatidylinositol\/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis","volume":"73","author":"Fondevila","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.08.029_bib33","first-page":"22","article-title":"Lipids and antiplatelet therapy: important considerations and future perspectives","author":"Dukanovic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00216-020-02996-9","article-title":"Analysis of serum lysophosphatidylethanolamine levels in patients with non-alcoholic fatty liver disease by liquid chromatography-tandem mass spectrometry","volume":"413","author":"Yamamoto","year":"2021","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jhep.2023.08.029_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/nu10050649","article-title":"Circulating phospholipid patterns in NAFLD patients associated with a combination of metabolic risk factors","volume":"10","author":"Tiwari-Heckler","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2023.08.029_bib36","first-page":"22","article-title":"2-Arachidonyl-lysophosphatidylethanolamine induces anti-inflammatory effects on macrophages and in carrageenan-induced paw edema","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/nu14030579","article-title":"Lysophosphatidylethanolamine affects lipid accumulation and metabolism in a human liver-derived cell line","volume":"14","author":"Yamamoto","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2023.08.029_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4062\/biomolther.2016.046","article-title":"Calcium signaling of lysophosphatidylethanolamine through LPA(1) in human SH-SY5Y neuroblastoma cells","volume":"25","author":"Lee","year":"2017","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.jhep.2023.08.029_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00232-020-00133-2","article-title":"The lysophosphatidylserines-an emerging class of signalling lysophospholipids","volume":"253","author":"Shanbhag","year":"2020","journal-title":"J\u00a0Membr Biol"},{"key":"10.1016\/j.jhep.2023.08.029_bib40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12013-021-00988-9","article-title":"Current knowledge on the biology of lysophosphatidylserine as an emerging bioactive lipid","volume":"79","author":"Omi","year":"2021","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.jhep.2023.08.029_bib41","doi-asserted-by":"crossref","first-page":"48122","DOI":"10.1074\/jbc.M206941200","article-title":"A\u00a0novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization","volume":"277","author":"van der Kleij","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.08.029_bib42","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1038\/s41598-020-59590-3","article-title":"Possible involvement of PS-PLA1 and lysophosphatidylserine receptor (LPS1) in hepatocellular carcinoma","volume":"10","author":"Uranbileg","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.prostaglandins.2009.04.009","article-title":"Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol","volume":"89","author":"Makide","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jhep.2023.08.029_bib44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3858\/emm.2009.41.8.064","article-title":"Lysophosphatidylglycerol inhibits formyl peptide receptorlike-1-stimulated chemotactic migration and IL-1beta production from human phagocytes","volume":"41","author":"Shim","year":"2009","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib46","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1021\/pr200629p","article-title":"A\u00a0comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations","volume":"10","author":"Garcia-Canaveras","year":"2011","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib48","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.28973","article-title":"Hepatocyte autotaxin expression promotes liver fibrosis and cancer","volume":"65","author":"Kaffe","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1194\/jlr.M700184-JLR200","article-title":"Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes","volume":"49","author":"Han","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbalip.2013.11.013","article-title":"Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function","volume":"1841","author":"Hollie","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2023.08.029_bib51","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.1400699","article-title":"Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease","volume":"193","author":"Maricic","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2023.08.029_bib52","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3389\/fimmu.2019.02927","article-title":"Lysophosphatidylcholine induces NLRP3 inflammasome-mediated foam cell formation and pyroptosis in human monocytes and endothelial cells","volume":"10","author":"Correa","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.08.029_bib53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.22433","article-title":"The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in mice","volume":"48","author":"Johnson","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.659211","article-title":"The G2A receptor deficiency aggravates atherosclerosis in rats by regulating macrophages and lipid metabolism","volume":"12","author":"Cui","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhep.2023.08.029_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2016.27","article-title":"Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects","volume":"6","author":"Ma","year":"2016","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jhep.2023.08.029_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.25630","article-title":"Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis","volume":"56","author":"Tanaka","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib57","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3389\/fonc.2019.01069","article-title":"Metabolomic profiles for HBV related hepatocellular carcinoma including alpha-fetoproteins positive and negative subtypes","volume":"9","author":"Sun","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2023.08.029_bib58","article-title":"Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication","volume":"3","author":"Israelsen","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prostaglandins.2016.06.001","article-title":"Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis","volume":"124","author":"Krautbauer","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jhep.2023.08.029_bib60","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2022.10.031","article-title":"Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure","volume":"78","author":"Trovato","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","article-title":"Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis","volume":"70","author":"Banales","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.08.029_bib62","doi-asserted-by":"crossref","first-page":"14021","DOI":"10.1021\/bi061657l","article-title":"Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine","volume":"45","author":"Ojala","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.jhep.2023.08.029_bib63","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cca.2011.03.014","article-title":"Autotaxin as a novel serum marker of liver fibrosis","volume":"412","author":"Nakagawa","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhep.2023.08.029_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/srep30847","article-title":"Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases","volume":"6","author":"Wunsch","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103532","article-title":"Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study","volume":"9","author":"Pleli","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.08.029_bib66","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/hepr.13382","article-title":"Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"49","author":"Honda","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/hepr.12997","article-title":"Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection","volume":"48","author":"Joshita","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib68","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1038\/s41598-018-26531-0","article-title":"Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis","volume":"8","author":"Joshita","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib69","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.celrep.2019.10.024","article-title":"Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis","volume":"29","author":"Dobie","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.mcg.0000225642.90898.0e","article-title":"Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C","volume":"41","author":"Watanabe","year":"2007","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2023.08.029_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/srep46705","article-title":"Association of serum autotaxin levels with liver fibrosis in patients with chronic hepatitis C","volume":"7","author":"Yamazaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.08.029_bib72","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s11605-007-0322-9","article-title":"Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?","volume":"11","author":"Cooper","year":"2007","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jhep.2023.08.029_bib73","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jhep.2017.01.009","article-title":"Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication","volume":"66","author":"Farquhar","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib74","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/oby.21232","article-title":"Serum Autotaxin\/ENPP2 correlates with insulin resistance in older humans with obesity","volume":"23","author":"Reeves","year":"2015","journal-title":"Obesity"},{"key":"10.1016\/j.jhep.2023.08.029_bib75","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000480470","article-title":"Lysophosphatidic acid inhibits insulin signaling in primary rat hepatocytes via the LPA3 receptor subtype and is increased in obesity","volume":"43","author":"Fayyaz","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jhep.2023.08.029_bib76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/oby.20960","article-title":"Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity","volume":"23","author":"Rachakonda","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2023.08.029_bib77","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1194\/jlr.M014985","article-title":"Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid","volume":"52","author":"Dusaulcy","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib78","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.2337\/db13-1694","article-title":"ENPP2 contributes to adipose tissue expansion and insulin resistance in diet-induced obesity","volume":"63","author":"Nishimura","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2023.08.029_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208099","article-title":"Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity","volume":"14","author":"Brandon","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.08.029_bib80","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00125-013-2891-3","article-title":"Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice","volume":"56","author":"Rancoule","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.08.029_bib81","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00109-007-0269-z","article-title":"Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake","volume":"86","author":"Yea","year":"2008","journal-title":"J\u00a0Mol Med (Berlin, Germany)"},{"key":"10.1016\/j.jhep.2023.08.029_bib82","first-page":"G1091","article-title":"Characterization of sphingosine 1-phosphate-induced actions and its signaling pathways in rat hepatocytes","volume":"272","author":"Im","year":"1997","journal-title":"The Am J Physiol"},{"key":"10.1016\/j.jhep.2023.08.029_bib83","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/0008-5472.CAN-17-1624","article-title":"LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response","volume":"78","author":"Ha","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcmgh.2022.07.012","article-title":"Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the PPARalpha\/FGF21 Axis","volume":"14","author":"Qiu","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib85","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol Rev Cambridge Philosophical Soc"},{"key":"10.1016\/j.jhep.2023.08.029_bib86","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jss.2009.09.005","article-title":"Hepatocellular carcinoma associated lipid metabolism reprogramming","volume":"169","author":"Skill","year":"2011","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib87","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2023.08.029_bib88","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/onc.2010.517","article-title":"Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression","volume":"30","author":"Park","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2023.08.029_bib89","doi-asserted-by":"crossref","first-page":"66154","DOI":"10.18632\/oncotarget.19825","article-title":"EDG2 enhanced the progression of hepatocellular carcinoma by LPA\/PI3K\/AKT\/mTOR signaling","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2023.08.029_bib90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00109-019-01862-1","article-title":"Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function","volume":"98","author":"Gnocchi","year":"2020","journal-title":"J\u00a0Mol Med (Berlin, Germany)"},{"key":"10.1016\/j.jhep.2023.08.029_bib91","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.omto.2022.08.001","article-title":"Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model","volume":"26","author":"Ren","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jhep.2023.08.029_bib92","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jss.2012.10.054","article-title":"Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma","volume":"180","author":"Sokolov","year":"2013","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161825","article-title":"Higher LPA2 and LPA6 mRNA levels in hepatocellular carcinoma are associated with poorer differentiation, microvascular invasion and earlier recurrence with higher serum autotaxin levels","volume":"11","author":"Enooku","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.08.029_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-9-71","article-title":"Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma","volume":"9","author":"Wu","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2023.08.029_bib95","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-019-11274-x","article-title":"ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy","volume":"10","author":"Tian","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.08.029_bib96","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.08.029_bib97","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1194\/jlr.R057588","article-title":"Cytosolic phospholipase A(2): physiological function and role in disease","volume":"56","author":"Leslie","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib98","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1021\/cr2002992","article-title":"Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis","volume":"111","author":"Smith","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.jhep.2023.08.029_bib99","doi-asserted-by":"crossref","first-page":"20434","DOI":"10.1073\/pnas.0808211106","article-title":"The nuclear membrane organization of leukotriene synthesis","volume":"105","author":"Mandal","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.08.029_bib100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10555-010-9264-x","article-title":"Cytochrome P450-derived eicosanoids: the neglected pathway in cancer","volume":"29","author":"Panigrahy","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jhep.2023.08.029_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28062622","article-title":"Deciphering complex interactions in bioactive lipid signaling","volume":"28","author":"Maccarrone","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2023.08.029_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114732","article-title":"Role of eicosanoids in liver repair, regeneration and cancer","volume":"192","author":"Alvarez","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2023.08.029_bib103","first-page":"11","article-title":"The roles of various prostaglandins in fibrosis: a review","author":"Li","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jhep.2023.08.029_bib104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbadis.2017.11.001","article-title":"PGE(2) induces apoptosis of hepatic stellate cells and attenuates liver fibrosis in mice by downregulating miR-23a-5p and miR-28a-5p","volume":"1864","author":"Brea","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2023.08.029_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658840","article-title":"Resolution-based therapies: the potential of lipoxins to treat human diseases","volume":"12","author":"Jaen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.08.029_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106380","article-title":"Lipoxin A(4) inhibited the activation of hepatic stellate cells -T6 cells by modulating profibrotic cytokines and NF-kappaB signaling pathway","volume":"146","author":"Zhang","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jhep.2023.08.029_bib107","doi-asserted-by":"crossref","first-page":"745","DOI":"10.5152\/tjg.2019.18276","article-title":"A\u00a0bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes","volume":"30","author":"Kurtoglu","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.08.029_bib108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5152\/eurasianjmed.2022.20030","article-title":"Influence of lipoxin-A4 treatment on cytokine, chemokine genes expression, and phenotypic distribution of lymphocyte subsets during experimental liver fibrosis","volume":"54","author":"Karaca","year":"2022","journal-title":"Eurasian J Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib109","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/0006-2952(88)90248-1","article-title":"Leukotriene-mediated liver injury","volume":"37","author":"Tiegs","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2023.08.029_bib110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.08.029_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106400","article-title":"Cytochrome P450-derived eicosanoids and inflammation in liver diseases","volume":"147","author":"Shoieb","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jhep.2023.08.029_bib112","first-page":"2456","article-title":"Targeting the eicosanoid pathway in hepatocellular carcinoma","volume":"11","author":"Razdan","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib113","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.5114\/aoms.2016.61916","article-title":"Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis","volume":"12","author":"Chen","year":"2016","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib114","first-page":"1410","article-title":"Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398","volume":"7","author":"Bae","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib115","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.2147\/CMAR.S183376","article-title":"Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2","volume":"11","author":"Tai","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib116","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/stem.2821","article-title":"PGD2\/PTGDR2 signaling restricts the self-renewal and tumorigenesis of gastric cancer","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.jhep.2023.08.029_bib117","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.cdd.4400908","article-title":"Lipoxygenases and their involvement in programmed cell death","volume":"8","author":"Maccarrone","year":"2001","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jhep.2023.08.029_bib118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.smim.2017.09.005","article-title":"The yin and yang of leukotriene B(4) mediated inflammation in cancer","volume":"33","author":"Jala","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jhep.2023.08.029_bib119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.08.029_bib120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2013.10.006","article-title":"Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases","volume":"19","author":"Spite","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.08.029_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101689","article-title":"Role of n-3 polyunsaturated fatty acids in ameliorating the obesity-induced metabolic syndrome in animal models and humans","volume":"17","author":"Huang","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.799492","article-title":"Resolvin E1-ChemR23 Axis regulates the hepatic metabolic and inflammatory transcriptional landscape in obesity at the whole genome and exon level","volume":"8","author":"Al-Shaer","year":"2021","journal-title":"Front Nutr"},{"key":"10.1016\/j.jhep.2023.08.029_bib123","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1096\/fj.201600859R","article-title":"Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob\/ob and diet-induced obese mice","volume":"31","author":"Martinez-Fernandez","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2023.08.029_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106961","article-title":"Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-kappaB and MAPK pathways and activating the Nrf2 pathway in mice","volume":"88","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jhep.2023.08.029_bib125","doi-asserted-by":"crossref","first-page":"587","DOI":"10.21037\/hbsn.2019.08.07","article-title":"Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis","volume":"9","author":"Abshagen","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhep.2023.08.029_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2022.106634","article-title":"The role of Resolvin D1 in liver diseases","volume":"160","author":"Yang","year":"2022","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jhep.2023.08.029_bib127","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3892\/etm.2014.1641","article-title":"Resolvin E1 reduces hepatic fibrosis in mice with Schistosoma japonicum infection","volume":"7","author":"Qiu","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.yexmp.2015.02.005","article-title":"Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis","volume":"98","author":"Pohl","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jhep.2023.08.029_bib129","article-title":"Maresin 1, a proresolving lipid mediator, mitigates carbon tetrachloride-induced liver injury in mice","volume":"2016","author":"Li","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jhep.2023.08.029_bib130","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1096\/fj.201700394R","article-title":"The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress","volume":"31","author":"Rius","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2023.08.029_bib131","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1172\/JCI124219","article-title":"A\u00a0maresin 1\/RORalpha\/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis","volume":"129","author":"Han","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.08.029_bib132","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.03.005","article-title":"Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors","volume":"58","author":"Chiang","year":"2017","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib133","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.08.029_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2020.102095","article-title":"Omega-3 derivatives, specialized pro-resolving mediators: promising therapeutic tools for the treatment of pain in chronic liver disease","volume":"158","author":"Mariqueo","year":"2020","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jhep.2023.08.029_bib135","first-page":"3603","article-title":"Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC\/PRF\/5 hepatocellular carcinoma cells by targeting the MAPK pathway","volume":"16","author":"Lu","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib136","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1096\/fj.13-235614","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2023.08.029_bib137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2023.08.029_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143333","article-title":"The impact of resolution of inflammation on tumor microenvironment: exploring new ways to control cancer progression","volume":"14","author":"Liotti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2023.08.029_bib139","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.20170681","article-title":"Resolvins suppress tumor growth and enhance cancer therapy","volume":"215","author":"Sulciner","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-021-01937-3","article-title":"Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes","volume":"40","author":"Mattoscio","year":"2021","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib141","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13046-019-1163-6","article-title":"Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP","volume":"38","author":"Sun","year":"2019","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2023.08.029_bib142","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Di Marzo","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2023.08.029_bib143","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jhep.2023.08.029_bib144","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.08.029_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153960","article-title":"Schisandrin B targets cannabinoid 2 receptor in Kupffer cell to ameliorate CCl(4)-induced liver fibrosis by suppressing NF-kappaB and p38 MAPK pathway","volume":"98","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jhep.2023.08.029_bib146","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.08.029_bib147","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3100943","article-title":"Transient receptor potential vanilloid-1 (TRPV1) alleviates hepatic fibrosis via TGF-beta signaling","volume":"2022","author":"Qian","year":"2022","journal-title":"Dis Markers"},{"key":"10.1016\/j.jhep.2023.08.029_bib148","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/imm.12441","article-title":"Endocannabinoid signalling in innate and adaptive immunity","volume":"144","author":"Chiurchiu","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.jhep.2023.08.029_bib149","first-page":"23","article-title":"Cannabinoids and chronic liver diseases","author":"Mboumba Bouassa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/0929867327666200303122734","article-title":"The effect of CB1 antagonism on hepatic oxidative\/nitrosative stress and inflammation in nonalcoholic fatty liver disease","volume":"28","author":"Jorgacevic","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2023.08.029_bib151","first-page":"21","article-title":"The endocannabinoid system: a target for cancer treatment","author":"Laezza","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.08.029_bib152","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/labinvest.2011.62","article-title":"Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor","volume":"91","author":"Huang","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2023.08.029_bib153","doi-asserted-by":"crossref","first-page":"G1150","DOI":"10.1152\/ajpgi.90455.2008","article-title":"The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway","volume":"295","author":"DeMorrow","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2023.08.029_bib154","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2006.03.005","article-title":"The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells","volume":"9","author":"Carracedo","year":"2006","journal-title":"Cancer Cell"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823050997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823050997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:14:40Z","timestamp":1774314880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823050997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0168827823050997"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.08.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioactive signalling lipids as drivers of chronic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}